Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIAXIN XL vs AZITHROMYCIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting m RNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.
Acute bacterial exacerbation of chronic obstructive pulmonary disease,Acute maxillary sinusitis,Community-acquired pneumonia,Pharyngitis/tonsillitis caused by Streptococcus pyogenes,Uncomplicated skin and skin structure infections,Mycobacterium avium complex infection (prevention and treatment),Helicobacter pylori infection (in combination with other drugs)
Acute bacterial exacerbations of chronic obstructive pulmonary disease due to H. influenzae, M. catarrhalis, or S. pneumoniae,Acute bacterial sinusitis due to H. influenzae, M. catarrhalis, or S. pneumoniae,Community-acquired pneumonia due to C. pneumoniae, H. influenzae, M. pneumoniae, or S. pneumoniae,Pharyngitis/tonsillitis due to S. pyogenes,Uncomplicated skin and skin structure infections due to S. aureus, S. pyogenes, or S. agalactiae,Urethritis/cervicitis due to C. trachomatis or N. gonorrhoeae,Genital ulcer disease due to H. ducreyi,Acute otitis media due to H. influenzae, M. catarrhalis, or S. pneumoniae,Prevention of disseminated M. avium complex disease in advanced HIV infection,Pertussis (off-label)
500 mg orally once daily for 7 to 14 days
500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.
Terminal elimination half-life is 5-7 hours in healthy adults; prolonged to 20-40 hours in patients with severe hepatic impairment (Child-Pugh Class C).
Terminal half-life of approximately 68 hours (range 35–96 h) after multiple doses, allowing once-daily dosing and a prolonged post-antibiotic effect.
Primarily metabolized by the cytochrome P450 system, mainly CYP3A4, to active metabolites such as 14-hydroxyclarithromycin.
Primarily hepatic, not via cytochrome P450 system. Partially metabolized to inactive metabolites. Eliminated via biliary excretion and renal excretion (<15% unchanged).
Approximately 20-30% of the dose is excreted unchanged in urine, with the remainder as metabolites (primarily via biliary/fecal elimination). Renal clearance accounts for about 12% of total clearance.
Primarily biliary/fecal (approx. 50% unchanged); renal excretion accounts for about 12% of the dose.
Approximately 70% bound to plasma proteins, primarily to albumin and alpha-1-acid glycoprotein.
7–51% (concentration-dependent); primarily binds to albumin.
Volume of distribution is 3-4 L/kg, indicating extensive tissue penetration (e.g., lungs, sinuses, tonsils).
31.1 L/kg (range 23–50 L/kg), indicating extensive tissue penetration and sequestration (e.g., WBCs, liver, lung).
Oral bioavailability is approximately 50% due to first-pass metabolism; food does not significantly affect the extended-release formulation.
Oral: 37–40% (fasting); food may decrease absorption by ~50%.
Cr Cl <30 m L/min: 500 mg orally once daily or 250 mg twice daily. Cr Cl <30 m L/min not recommended for BIAXIN XL due to decreased clearance.
No dose adjustment required for GFR ≥10 m L/min. For GFR <10 m L/min, caution advised; no specific dose recommendation, consider alternative agent.
Child-Pugh Class C: reduce dose by 50% or consider alternative therapy. Child-Pugh Class A or B: no adjustment necessary.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh class A and B). Contraindicated in severe hepatic impairment (Child-Pugh class C).
Not approved for use in children less than 12 years of age. For children ≥12 years: same as adult dosing.
For otitis media and community-acquired pneumonia: 10 mg/kg orally or IV on day 1 (max 500 mg), then 5 mg/kg (max 250 mg) once daily on days 2-5. For pharyngitis/tonsillitis: 12 mg/kg orally once daily for 5 days (max 500 mg/day).
Increased risk of QT prolongation. Monitor renal function and consider dose adjustment based on creatinine clearance. No specific dose adjustment is recommended solely for age.
No specific dose adjustment required; use same dosing as younger adults. Monitor renal function due to age-related decline, but no modification needed unless severe renal impairment (Cr Cl <10 m L/min).
No FDA boxed warning.
None.
Increased risk of cardiac arrhythmias (QT prolongation, torsades de pointes) in patients with pre-existing cardiac conditions or electrolyte abnormalities,Hepatotoxicity, including hepatic failure and jaundice,Exacerbation of myasthenia gravis symptoms,Increased risk of colchicine toxicity when used with P-glycoprotein inhibitors,Potential for drug interactions due to CYP3A4 inhibition
Hepatotoxicity: hepatitis, cholestatic jaundice, hepatic necrosis, hepatic failure,QT prolongation and torsades de pointes (especially with concurrent use of other QT-prolonging agents, electrolyte abnormalities, bradycardia, or structural heart disease),Clostridioides difficile-associated diarrhea (CDAD),Aggravation of myasthenia gravis,Severe allergic reactions (angioedema, anaphylaxis, Stevens-Johnson syndrome),Infantile hypertrophic pyloric stenosis (IHPS) in neonates following oral azithromycin,Use in pregnancy: category B; avoid during breastfeeding due to potential for disruption of infant gut flora
Hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic,Concomitant use with ergotamine or dihydroergotamine,Concomitant use with HMG-Co A reductase inhibitors that are extensively metabolized by CYP3A4 (e.g., lovastatin, simvastatin),Concomitant use with pimozide,History of cholestatic jaundice or hepatic dysfunction associated with prior clarithromycin use,QTc prolongation or cardiac arrhythmia history (relative contraindication)
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic,History of cholestatic jaundice or hepatic dysfunction associated with prior azithromycin use,Concurrent use with ergotamine or dihydroergotamine (possible ergot toxicity)
Take with food to enhance absorption and reduce GI intolerance. Avoid grapefruit and grapefruit juice as they may alter drug metabolism. No other significant food interactions.
Food does not significantly affect absorption; can be taken with or without food. However, avoiding high-fat meals may reduce minor GI side effects. No known specific food interactions.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but maternal toxicity at high doses produced fetal malformations. Second and third trimesters: No known fetal risks from limited human studies; however, due to rare reports of pyloric stenosis in infants exposed to macrolides late in pregnancy, consider risk-benefit. Overall, use only if clearly needed.
FDA Category B. No evidence of teratogenicity in animal studies; limited human data show no increased risk of major malformations. First trimester: No significant association with birth defects. Second/third trimester: No reported fetal harm from short-term use for infections like chorioamnionitis. Use only if clearly needed.
Clarithromycin is excreted into breast milk. M/P ratio is approximately 1.0 (based on total drug). Consider the potential for infant gastrointestinal effects (diarrhea, candidiasis) and theoretical risk of antibiotic-associated colitis. Compatible with breastfeeding with monitoring for adverse effects in the infant.
Azithromycin is excreted into breast milk in low amounts. M/P ratio approximately 0.2-0.6. Relative infant dose estimated at 2-6% of maternal weight-adjusted dose. Generally considered compatible with breastfeeding; monitor infant for diarrhea or rash.
No specific dose adjustments are recommended for pregnancy; however, pharmacokinetic changes (increased volume of distribution, altered clearance) may occur, but clinical significance is not established. Use standard adult dosing with caution.
No dose adjustment required for pregnancy. Standard adult dosing (500 mg on day 1, then 250 mg daily for 4 days) is appropriate. Note: Pregnancy may increase volume of distribution, but pharmacokinetic studies suggest no significant decrease in AUC; no need for dose increase.
BIAXIN XL (clarithromycin extended-release) is a macrolide antibiotic with a long half-life allowing once-daily dosing. It is a strong CYP3A4 inhibitor, increasing levels of many drugs including statins, warfarin, and oral contraceptives. Prolongs QT interval; avoid in patients with known QTc prolongation or concurrent use of other QT-prolonging agents. Common adverse effects include metallic taste and gastrointestinal upset. Monitor liver function in hepatic impairment.
Monitor for QTc prolongation especially in patients with preexisting cardiac conditions or those on other QT-prolonging drugs. Azithromycin has a long half-life (68 hours) allowing for shorter treatment courses. Use with caution in hepatic impairment; consider alternative in severe liver disease. Not recommended for pneumonia in patients with bacteremia due to increased mortality risk. Administer on an empty stomach or with food if GI upset occurs; however, absorption is unaffected by food.
Take with food to reduce stomach upset.,Do not crush or chew the tablet; swallow whole.,Complete the full course even if you feel better.,Avoid alcohol during treatment.,Inform your doctor about all medications, including OTC and herbal supplements, due to drug interactions.,Report symptoms of arrhythmia (dizziness, palpitations, fainting) or severe diarrhea.,May cause metallic taste; this is temporary.,Use alternate contraception if on oral contraceptives due to interaction.
Take exactly as prescribed; do not skip doses or stop early even if you feel better.,Do not take antacids containing aluminum or magnesium within 2 hours before or after this medication.,Report any signs of liver problems (nausea, vomiting, dark urine, jaundice) or severe diarrhea (watery or bloody) immediately.,Azithromycin may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Inform your doctor if you have a history of QT prolongation, heart rhythm problems, or electrolyte imbalances.,Store at room temperature away from moisture and heat; discard any unused liquid after 10 days.
No interactions on record
"Azithromycin, a macrolide antibiotic, is known to prolong the QT interval by blocking cardiac potassium channels (specifically IKr), which can lead to torsades de pointes. Mifepristone also poses a risk of QT prolongation, likely via similar mechanisms. Coadministration may result in additive QTc prolongation, increasing the risk of life-threatening ventricular arrhythmias, especially in patients with preexisting cardiac conditions or electrolyte disturbances."
"Lumiracoxib is a selective COX-2 inhibitor primarily metabolized by CYP2C9 and to a lesser extent by CYP3A4. Azithromycin, a macrolide antibiotic, is a known inhibitor of CYP3A4. Concomitant use may decrease the metabolism of azithromycin, leading to increased plasma concentrations and potential toxicity, such as QT prolongation and hepatotoxicity. Elevated azithromycin levels can also enhance its antibacterial effects but raise safety concerns."
"Azithromycin, a macrolide antibiotic, inhibits the cardiac potassium channel encoded by hERG (human Ether-à-go-go-Related Gene), leading to prolonged cardiac repolarization and increased risk of QTc interval prolongation. Arformoterol, a long-acting beta-2 agonist, can also prolong the QTc interval via beta-adrenergic receptor-mediated effects on cardiac ion channels. Concurrent use may result in additive QTc prolongation, predisposing patients to potentially fatal ventricular arrhythmias such as torsades de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIAXIN XL vs AZITHROMYCIN, answered by our medical review team.
BIAXIN XL is a Macrolide Antibiotic that works by Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.. AZITHROMYCIN is a Macrolide Antibiotic that works by Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting m RNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIAXIN XL and AZITHROMYCIN depend on the specific clinical indication. These are both Macrolide Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIAXIN XL is: 500 mg orally once daily for 7 to 14 days. The standard adult dose of AZITHROMYCIN is: 500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIAXIN XL and AZITHROMYCIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIAXIN XL is classified as Category C. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses, but maternal toxicity at high doses produced fetal ma. AZITHROMYCIN is classified as Category A/B. FDA Category B. No evidence of teratogenicity in animal studies; limited human data show no increased risk of major malformations. First trimester: No significant association with . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.